Institute for Research in Biomedicine

The United States of America, As Represented by the Secretary, Department of Health and Human Services

Humabs Biomed Sa

Medimmune Limited

Humabs, LLC

University of Washington

US Government As Represented by the Secretary of the Army

Other

Centre Hospitalier Universitaire Vaudois

Micromet Ag

The Pirbright Institute

Institute of Research in Biomedicine

Amgen Research Gmbh

Antonio Lanzavecchia

Annalisa Macagno

Davide Corti

Baoshan Zhang

Nicole Kallewaard-LeLay

Qing Zhu

Andy Q Yuan

Josephine Mary McAuliffe

Ebony Benjamin

Leslie Wachter

Guillaume Stewart-Jones

Yongping Yang

Peter D Kwong

Peter L Collins

Ursula J Buchholz

Michael Gordon Joyce

David Baker

Neil P King

Gwo-Yu Chuang

Wing-Pui Kong

Lance Joseph Stewart

Aliaksandr Druz

Yaroslav Tsybovsky

Li Ou

Kai Xu

Frances Palmer-Hill

Anna DeMarco

Laurent Perez

Jessica Marcandalli

Barbara Guarino

John R Mascola

Barney S Graham

Tongqing Zhou

Nancy J Sullivan

Julie Ledgerwood

Paul Thomas

Brooke Fiala

Luca Piccoli

Sabue Mulangu

Jean-Jacques Muyembe-Tamfun

John Trefry

Daphne Stanley

John Mascola

Giuseppe Pantaleo

Jorge Fallas

Lei Chen

Yang Hsia

Wing-pui Kong

Brooke Nickerson

Roger Geiger

Federica Sallusto

Geraldine Taylor

David Jarrossay

Jean Christophe Sabue Mulangu

Barncy Graham

Embodiments of a recombinant human Parainfluenza Virus (hPIV) F ectodomain trimer stabilized in a prefusion conformation are provided. Also disclosed are nucleic acids encoding the hPIV F ectodomain trimer and methods of producing the hPIV F ectodomain trimer. Methods for inducing an immune response in a subject are also disclosed. In some embodiments, the method can be a method for treating or inhibiting a hPIV infection in a subject by administering a effective amount of the recombinant hPIV F ectodomain trimer to the subject.

Prefusion PIV F immunogens and their use

The present invention provides engineered antibodies and antigen binding fragments, in which an additional functional domain is inserted into the elbow region of the antibody or antigen binding fragment. The present invention also provides nucleic acid molecules, such as vectors, encoding such antibodies and antigen binding fragments, host cells and compositions comprising such antibodies, antigen binding fragments or nucleic acid molecules and uses thereof. For example a multispecific antibody format is provided, in which an additional binding site (specificity) is inserted into the elbow region of an antibody or antigen binding fragment.

Antibodies with functional domains in the elbow region between variable and constant domain

The invention relates to antibodies and antigen binding fragments thereof that are capable of binding to influenza B virus hemagglutinin (HA) and neutralizing influenza B virus in two phylogenetically distinct lineages. In one embodiment, the antibody or antigen binding fragment is capable of binding to influenza B virus hemagglutinin and neutralizing influenza B virus in Yamagata and Victoria lineages.

Neutralizing anti-influenza B antibodies and uses thereof

Disclosed herein are nanostructures and their use, where the nanostructures include

Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus F proteins and their use

Metapneumovirus (MPV) F proteins stabilized in a prefusion conformation, nucleic acid molecules and vectors encoding these proteins, and methods of their use and production are disclosed. In several embodiments, the MPV F proteins and/or nucleic acid molecules can be used to generate an immune response to MPV in a subject. In additional embodiments, the therapeutically effective amount of the MPV F ectodomain trimers and/or nucleic acid molecules can be administered to a subject in a method of treating or preventing MPV infection.

Recombinant metapneumovirus f proteins and their use

The invention relates to antibodies and binding fragments thereof that are capable of binding to influenza A virus hemagglutinin and neutralizing at least one group 1 subtype and at least 1 group 2 subtype of influenza A virus.

Neutralizing anti-influenza A antibodies and uses thereof

Neutralizing anti-influenza b antibodies and uses thereof

Recombinant metapneumovirus F proteins and their use

Disclosed herein are nanostructures and their use, where the nanostructures include (a) a plurality of first assemblies, each first assembly comprising a plurality of identical first polypeptides; (b) a plurality of second assemblies, each second assembly comprising a plurality of identical second polypeptides, wherein the second polypeptide differs from the first polypeptide; wherein the plurality of first assemblies non-covalently interact with the plurality of second assemblies to form a nanostructures; and wherein the nanostructure displays multiple copies of one or more paramyxovirus and/or pneumovirus F proteins or antigenic fragments thereof, on an exterior of the nanostructure.

The present invention provides multispecific antibodies, and antigen binding fragments thereof, that potently neutralize a cytokine and that may thus be useful in the prevention and/or treatment of inflammatory and/or autoimmune diseases. In particular, the present invention provides a multispecific antibody, or an antigen binding fragment thereof, comprising at least two different domains specifically binding to at least two different, non-overlapping sites in a cytokine and an Fc moiety. The invention also relates to nucleic acids that encode such antibodies and antibody fragments and immortalized B cells and cultured plasma cells that produce such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies and antibody fragments of the invention in screening methods as well as in the diagnosis, prophylaxis and treatment of inflammatory and/or autoimmune diseases.

Ultra-potent neutralization of GM-CSF by multispecific antibodies and uses thereof

The invention relates to antibodies and binding fragments thereof that are capable of binding to influenza A virus hemagglutinin and neutralizing at least one group 1 subtype and at least 1 group 2 subtype of influenza A virus. In one embodiment, an antibody or binding fragment according to the invention is capable of binding to and/or neutralizing one or more influenza A virus group 1 subtypes selected from H1, H2, H5, H6, H8, H9, H11, H12, H13, H16 and H17 and variants thereof and one or more influenza A virus group 2 subtype selected from H3, H4, H7, H1, 0, H14 and H15 and variants thereof.

The present invention provides novel uses and methods for T cell based immunotherapies. Specifically, the invention relates to novel ligands, targets and nucleic acids and vectors encoding said targets that are useful for modulating T cell responses.

Arginine and its use as a T cell modulator

Growing community of inventors

Bellinzona, Switzerland

Antonio Lanzavecchia